Healthcare
Live Price
Offline$3.10
+2.31% today
1Y Change
-49.35%
Window
Jun 20, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 20, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Quanterix Corporation (QTRX) is a Healthcare stock with a market cap of $160.00M and listed on NASDAQ. The stock last traded around $3.10 and down 49.3% across the available one-year price window (Jun 20, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +2.6%, EPS growth of -151.0%, a dividend yield of 0.0%. What stands out right now is revenue +2.6%, EPS -151.0%, free cash flow -107.2% with operating margin -89.9% and ROIC -33.8%. Valuation is more restrained than many high-expectation growth names at price/sales 1.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines QTRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
QTRX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
QTRX Max Drawdown
-68.86%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for QTRX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$110.6M
+4.8% YoY
FY Net Income
-$55.5M
+44.2% YoY
Free Cash Flow
-$61.5M
-2.5% YoY
Revenue Growth
+2.6%
EPS Growth
-151.0%
Gross Margin
46.6%
Net Margin
-77.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 139M | 135M | 121M | 106M | 111M |
| Gross Profit | 65M | 81M | 73M | 45M | 65M |
| Operating Income | -87M | -53M | -46M | -104M | -57M |
| EBITDA | -68M | -44M | -36M | -68M | -52M |
| Net Income | -107M | -39M | -28M | -100M | -56M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 30M | 57M | 174M | 339M | 396M |
| Total Assets | 419M | 407M | 429M | 434M | 507M |
| Total Liabilities | 123M | 76M | 79M | 76M | 66M |
| Shareholder Equity | 296M | 330M | 350M | 358M | 441M |
| Total Debt | 37M | 37M | 41M | 44M | 22M |
| Net Debt | 7M | -19M | -133M | -295M | -375M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
48M
+0.8% YoY
Capital Expenditures
14M
-16.1% YoY
Free Cash Flow
62M
-2.5% YoY
Key ratios
Gross Margin
46.6%
Operating Margin
-89.9%
Net Margin
-77.2%
ROE
-35.2%
Debt / Equity
0.13x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.